In silico identification of novel CDK4 inhibitors for retinoblastoma

Retinoblastoma is a kind of cancer that mostly affects children's eyes, and this study intends to find drugs that can suppress the protein kinase cyclin-dependent kinase 4 (CDK4). CDK4 overexpression leads to the hyper-phosphorylation of RB tumor suppressor protein, which ultimately results in...

Full description

Saved in:
Bibliographic Details
Main Authors: Mukesh kumar, Vikas Srivastava, Uma Devi, KhemRaj Nackwal, Mohammad Z. Ahmed, Prakash K. Shukla
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Chemical Physics Impact
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667022424002871
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850270213605425152
author Mukesh kumar
Vikas Srivastava
Uma Devi
KhemRaj Nackwal
Mohammad Z. Ahmed
Prakash K. Shukla
author_facet Mukesh kumar
Vikas Srivastava
Uma Devi
KhemRaj Nackwal
Mohammad Z. Ahmed
Prakash K. Shukla
author_sort Mukesh kumar
collection DOAJ
description Retinoblastoma is a kind of cancer that mostly affects children's eyes, and this study intends to find drugs that can suppress the protein kinase cyclin-dependent kinase 4 (CDK4). CDK4 overexpression leads to the hyper-phosphorylation of RB tumor suppressor protein, which ultimately results in uncontrolled cell division. Aberration of cell cycle regulation, specifically the excessive expression of transcription factors responsible for uncontrolled cell division causes retinoblastoma progression. Hence, we screened 25,000 kinase-targeted small molecules against CDK-4 by Glide in Maestro, the top 11 were chosen based on docking scores, binding modes, chemical variety, and other parameters. We ran molecular dynamics (MD) simulations of top hits found in the docking studies and determined their free binding energy. This helped us to understand their thermodynamic and dynamic properties, as well as confirm the docking results, finally the two most promising ligands (3396 and 960) were obtained. As a result of our research, we have identified promising new compounds for treating retinoblastoma. To validate the possible therapeutic and preventative effects of this ligand, rigorous experimental validation, animal studies as well as clinical trials would be required.
format Article
id doaj-art-63bbde441ba04f92941f33a8e263ad74
institution OA Journals
issn 2667-0224
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Chemical Physics Impact
spelling doaj-art-63bbde441ba04f92941f33a8e263ad742025-08-20T01:52:44ZengElsevierChemical Physics Impact2667-02242024-12-01910074310.1016/j.chphi.2024.100743In silico identification of novel CDK4 inhibitors for retinoblastomaMukesh kumar0Vikas Srivastava1Uma Devi2KhemRaj Nackwal3Mohammad Z. Ahmed4Prakash K. Shukla5Department of Biophysics, All India Institute of Medical Sciences, New Delhi, IndiaSMAS, Galgotias University, Greater Noida, Uttar Pradesh, IndiaCentre for Bio-Separation Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, IndiaDepartment of Optometry, CT university, Ludhiana, IndiaDepartment of Pharmacognosy, college of Pharmacy, King Saud University, Riyadh, Saudi ArabiaCentre for Bio-Separation Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India; Corresponding author.Retinoblastoma is a kind of cancer that mostly affects children's eyes, and this study intends to find drugs that can suppress the protein kinase cyclin-dependent kinase 4 (CDK4). CDK4 overexpression leads to the hyper-phosphorylation of RB tumor suppressor protein, which ultimately results in uncontrolled cell division. Aberration of cell cycle regulation, specifically the excessive expression of transcription factors responsible for uncontrolled cell division causes retinoblastoma progression. Hence, we screened 25,000 kinase-targeted small molecules against CDK-4 by Glide in Maestro, the top 11 were chosen based on docking scores, binding modes, chemical variety, and other parameters. We ran molecular dynamics (MD) simulations of top hits found in the docking studies and determined their free binding energy. This helped us to understand their thermodynamic and dynamic properties, as well as confirm the docking results, finally the two most promising ligands (3396 and 960) were obtained. As a result of our research, we have identified promising new compounds for treating retinoblastoma. To validate the possible therapeutic and preventative effects of this ligand, rigorous experimental validation, animal studies as well as clinical trials would be required.http://www.sciencedirect.com/science/article/pii/S2667022424002871CDK4Drug discoveryRetinoblastomaEye researchMolecular dynamicsFree energy
spellingShingle Mukesh kumar
Vikas Srivastava
Uma Devi
KhemRaj Nackwal
Mohammad Z. Ahmed
Prakash K. Shukla
In silico identification of novel CDK4 inhibitors for retinoblastoma
Chemical Physics Impact
CDK4
Drug discovery
Retinoblastoma
Eye research
Molecular dynamics
Free energy
title In silico identification of novel CDK4 inhibitors for retinoblastoma
title_full In silico identification of novel CDK4 inhibitors for retinoblastoma
title_fullStr In silico identification of novel CDK4 inhibitors for retinoblastoma
title_full_unstemmed In silico identification of novel CDK4 inhibitors for retinoblastoma
title_short In silico identification of novel CDK4 inhibitors for retinoblastoma
title_sort in silico identification of novel cdk4 inhibitors for retinoblastoma
topic CDK4
Drug discovery
Retinoblastoma
Eye research
Molecular dynamics
Free energy
url http://www.sciencedirect.com/science/article/pii/S2667022424002871
work_keys_str_mv AT mukeshkumar insilicoidentificationofnovelcdk4inhibitorsforretinoblastoma
AT vikassrivastava insilicoidentificationofnovelcdk4inhibitorsforretinoblastoma
AT umadevi insilicoidentificationofnovelcdk4inhibitorsforretinoblastoma
AT khemrajnackwal insilicoidentificationofnovelcdk4inhibitorsforretinoblastoma
AT mohammadzahmed insilicoidentificationofnovelcdk4inhibitorsforretinoblastoma
AT prakashkshukla insilicoidentificationofnovelcdk4inhibitorsforretinoblastoma